Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals develops RNA-targeted and antisense medicines for serious diseases, with marketed products and a pipeline concentrated in neurology, cardiometabolic disease and selected high-need areas. Company news regularly covers commercial performance for TRYNGOLZA and DAWNZERA, royalty-generating partnered medicines such as SPINRAZA and WAINUA, and collaboration milestones tied to late-stage programs.
Recurring updates also include FDA and global regulatory reviews, clinical data presentations, and launch preparation for programs such as olezarsen in severe hypertriglyceridemia, zilganersen in Alexander disease and partnered bepirovirsen in chronic hepatitis B. Financial releases typically discuss product sales, royalty revenue, R&D collaboration revenue, operating expenses, cash resources and guidance, alongside governance matters such as annual meeting materials and board transitions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ionis Pharmaceuticals has announced that its partner Biogen received FDA approval for QALSODY (tofersen) as the first treatment targeting a genetic cause of amyotrophic lateral sclerosis (ALS)/b) associated with the gene mutation. This accelerated approval is based on a significant reduction of the neurofilament light chain, a biomarker linked to neuronal damage in ALS patients treated with QALSODY. The drug is administered via injection and aims to address the severe impact of SOD1 mutations, with ongoing trials to confirm clinical benefits. Notably, QALSODY joins another Ionis-developed drug, SPINRAZA, in tackling rare neurodegenerative diseases. However, approval is contingent on further demonstration of clinical efficacy from ongoing studies.
Ionis Pharmaceuticals announced successful results from its Phase 3 NEURO-TTRansform study for eplontersen, aimed at treating hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The study met all co-primary and secondary endpoints, with a significant reduction of 82% in serum TTR concentration among treated patients compared to an 11% reduction in the placebo group (p0.0001). Eplontersen also halted disease progression and improved quality of life, as measured by neuropathy impairment and quality of life scores. The findings, presented at AAN 2023, highlight eplontersen's potential as a new treatment option for patients with this fatal disease. The FDA has accepted a New Drug Application for eplontersen, with a PDUFA date set for December 22, 2023, while the company plans further regulatory submissions in Europe and beyond.